Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease
BackgroundThe global prevalence of non-alcoholic fatty liver disease (NAFLD) has surged, largely driven by modern lifestyle changes and dietary shifts. As these factors profoundly impact human health, exploring effective therapeutic strategies for NAFLD has become a pressing medical concern. Previou...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1564852/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849325359718203392 |
|---|---|
| author | Liyuan Hao Liyuan Hao Qing Peng Qing Peng Shenghao Li Shenghao Li Xiaoyu Hu Huimin Yan |
| author_facet | Liyuan Hao Liyuan Hao Qing Peng Qing Peng Shenghao Li Shenghao Li Xiaoyu Hu Huimin Yan |
| author_sort | Liyuan Hao |
| collection | DOAJ |
| description | BackgroundThe global prevalence of non-alcoholic fatty liver disease (NAFLD) has surged, largely driven by modern lifestyle changes and dietary shifts. As these factors profoundly impact human health, exploring effective therapeutic strategies for NAFLD has become a pressing medical concern. Previous studies have suggested that ginsenosides may offer a potential treatment approach for NAFLD by reducing oxidative stress and controlling inflammation. However, its efficacy and safety remain unclear. Therefore, the aim of this systematic review and meta-analysis is to evaluate the role of ginsenosides in the treatment of NAFLD.MethodsWe searched for relevant studies published through September 2024, including databases such as PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang Data. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) Animal Experiment Bias Risk Assessment Tool was used to evaluate the quality of the literature. Subsequently, Review Manager (RevMan, version 5.3) and STATA 15 software was utilized for data analysis.ResultsFinally, 30 studies involving a total of 604 animals were included in the analysis. The results showed that, compared with the model group, ginsenosides significantly reduces total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), low-density lipoprotein cholesterol (LDL), body weight, liver weight, liver index, serum insulin, tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6) and NAFLD Activity Score (NAS). Due to the high heterogeneity, we conducted subgroup analyses of the main results ALT, AST, TC and TG by animal strains, modeling methods, administration methods, ginsenoside dosages and types of ginsenosides. The results showed that the heterogeneity of TC may be derived from differences in modeling methods. The results showed that the heterogeneity of TC may be derived from differences in modeling methods.ConclusionIn this study, we summarized the molecular mechanism of ginsenosides in regulating NAFLD, mainly focusing on inhibiting inflammation and oxidative stress, improving insulin sensitivity, and regulating intestinal flora. Preclinical evidence indicates that ginsenosides represent a novel therapeutic avenue for NAFLD. The mechanism of ginsenosides in treating NAFLD may involve anti-inflammation, antioxidation, improving insulin resistance, and regulating intestinal flora. However, the inclusion of studies with low methodological quality and the existence of publication bias may undermine the validity of the results. To fully elucidate the mechanisms underlying the therapeutic effects of ginsenosides, future research should employ more rigorous experimental designs and conduct comprehensive investigations.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/. |
| format | Article |
| id | doaj-art-9a0d5fcc3f5e4d6592c4f32a286b56ad |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-9a0d5fcc3f5e4d6592c4f32a286b56ad2025-08-20T03:48:26ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-05-011610.3389/fphar.2025.15648521564852Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver diseaseLiyuan Hao0Liyuan Hao1Qing Peng2Qing Peng3Shenghao Li4Shenghao Li5Xiaoyu Hu6Huimin Yan7School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaDepartment of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaDepartment of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaSchool of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaDepartment of Integrated Traditional Chinese and Western Medicine Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaClinical Research Center, Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei, ChinaBackgroundThe global prevalence of non-alcoholic fatty liver disease (NAFLD) has surged, largely driven by modern lifestyle changes and dietary shifts. As these factors profoundly impact human health, exploring effective therapeutic strategies for NAFLD has become a pressing medical concern. Previous studies have suggested that ginsenosides may offer a potential treatment approach for NAFLD by reducing oxidative stress and controlling inflammation. However, its efficacy and safety remain unclear. Therefore, the aim of this systematic review and meta-analysis is to evaluate the role of ginsenosides in the treatment of NAFLD.MethodsWe searched for relevant studies published through September 2024, including databases such as PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang Data. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) Animal Experiment Bias Risk Assessment Tool was used to evaluate the quality of the literature. Subsequently, Review Manager (RevMan, version 5.3) and STATA 15 software was utilized for data analysis.ResultsFinally, 30 studies involving a total of 604 animals were included in the analysis. The results showed that, compared with the model group, ginsenosides significantly reduces total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), low-density lipoprotein cholesterol (LDL), body weight, liver weight, liver index, serum insulin, tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6) and NAFLD Activity Score (NAS). Due to the high heterogeneity, we conducted subgroup analyses of the main results ALT, AST, TC and TG by animal strains, modeling methods, administration methods, ginsenoside dosages and types of ginsenosides. The results showed that the heterogeneity of TC may be derived from differences in modeling methods. The results showed that the heterogeneity of TC may be derived from differences in modeling methods.ConclusionIn this study, we summarized the molecular mechanism of ginsenosides in regulating NAFLD, mainly focusing on inhibiting inflammation and oxidative stress, improving insulin sensitivity, and regulating intestinal flora. Preclinical evidence indicates that ginsenosides represent a novel therapeutic avenue for NAFLD. The mechanism of ginsenosides in treating NAFLD may involve anti-inflammation, antioxidation, improving insulin resistance, and regulating intestinal flora. However, the inclusion of studies with low methodological quality and the existence of publication bias may undermine the validity of the results. To fully elucidate the mechanisms underlying the therapeutic effects of ginsenosides, future research should employ more rigorous experimental designs and conduct comprehensive investigations.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/.https://www.frontiersin.org/articles/10.3389/fphar.2025.1564852/fullginsenosideanimal modelNAFLDpreclinical studiesmeta-analysis |
| spellingShingle | Liyuan Hao Liyuan Hao Qing Peng Qing Peng Shenghao Li Shenghao Li Xiaoyu Hu Huimin Yan Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease Frontiers in Pharmacology ginsenoside animal model NAFLD preclinical studies meta-analysis |
| title | Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease |
| title_full | Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease |
| title_fullStr | Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease |
| title_full_unstemmed | Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease |
| title_short | Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease |
| title_sort | novel insights from meta analysis the efficacy of ginsenosides in non alcoholic fatty liver disease |
| topic | ginsenoside animal model NAFLD preclinical studies meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1564852/full |
| work_keys_str_mv | AT liyuanhao novelinsightsfrommetaanalysistheefficacyofginsenosidesinnonalcoholicfattyliverdisease AT liyuanhao novelinsightsfrommetaanalysistheefficacyofginsenosidesinnonalcoholicfattyliverdisease AT qingpeng novelinsightsfrommetaanalysistheefficacyofginsenosidesinnonalcoholicfattyliverdisease AT qingpeng novelinsightsfrommetaanalysistheefficacyofginsenosidesinnonalcoholicfattyliverdisease AT shenghaoli novelinsightsfrommetaanalysistheefficacyofginsenosidesinnonalcoholicfattyliverdisease AT shenghaoli novelinsightsfrommetaanalysistheefficacyofginsenosidesinnonalcoholicfattyliverdisease AT xiaoyuhu novelinsightsfrommetaanalysistheefficacyofginsenosidesinnonalcoholicfattyliverdisease AT huiminyan novelinsightsfrommetaanalysistheefficacyofginsenosidesinnonalcoholicfattyliverdisease |